LumenAstra is commercializing a CU patent for a wearable, non-invasive sensor measuring core body temperature several centimeters below the skin with dramatic impact on cardiac surgery and brain protection after stroke and brain injury, increased efficacy of chemotherapy by targeted tumor warming, and a new generation of consumer thermometers. LumenAstra was awarded a non-dilutive $1 million NSF SBIR Phase II following their successful completion of the $256,000 Phase I. One huge benefit for any seed investor is that for every $2 invested, NSF will invest another $1. LumenAstra is also prequalified for the Colorado investment tax credit.
Funding Sought: $1 million Seed Round
For more information, contact Jim Pollock, jim@lumenastra.io